Skip to main content

Is tamoxifen a chemotherapy?

Is tamoxifen a chemotherapy?

Tamoxifen is a type of hormonal therapy known as a selective estrogen receptor modulator (SERM). The drug attaches to hormone receptors (specific proteins) in breast cancer cells. Once the medication is inside the cells, it stops the cancer from accessing the hormones they need to multiply and grow.

Who should not take tamoxifen?

A woman who has been diagnosed with any type of uterine cancer or atypical hyperplasia of the uterus (a kind of pre-cancer) should not take tamoxifen to help lower breast cancer risk. Raloxifene has not been tested in pre-menopausal women, so it should only be used if you have gone through menopause.

What does Oncotype score tell you?

The Oncotype DX Breast Recurrence Score Test analyzes the activity of 21 genes that can influence how likely a cancer is to grow and respond to treatment.

What foods should I avoid while taking tamoxifen?

Is there anything that I should avoid eating or drinking while on Tamoxifen?

  • Grapefruit. Grapefruit and grapefruit juice are well-known disruptors of numerous medications 2.
  • Turmeric/ Curcumin.
  • Black cohosh.
  • St.
  • St.
  • Ginseng.
  • Chamomile.
  • Soya.

Can I take vitamin C with tamoxifen?

Interactions between your drugs No interactions were found between tamoxifen and Vitamin C.

What can we learn from the NSABP B-06 trial?

The NSABP B-06 trial, along with other trials conducted by the Milan group to evaluate quadrantectomy, 4, 5 was instrumental in the establishment of breast conserving surgery plus radiotherapy as the preferred method of local treatment for patients with operable breast cancer.

How is the NSABP being evaluated in clinical trials?

The NSABP is currently accruing patients into protocol B-34, a double-blinded, placebo-controlled, randomized clinical trial evaluating oral clodronate as adjuvant therapy ( figure 15 ).

What is the eligibility criteria for the NSABP B-33 trial?

Schema of the NSABP B-33 trial evaluating adjuvant exemestane in postmenopausal patients who complete five years of tamoxifen and are recurrence-free. Eligible patients for the B-33 trial must have completed approximately 5 years of adjuvant tamoxifen therapy, must be postmenopausal, and disease free at the time of randomization.

What does NSABP do for US?

NSABP has led colorectal cancer research since 1977, leading dozens of clinical studies and engaging tens of thousands of participants. Current Colorectal Cancer Studies New standards of care for breast cancer, through trials led by NSABP, have saved millions of patients from mastectomy.